Please login to the form below

Not currently logged in
Email:
Password:

Zealand announces management changes

Firm making the roles of chief scientific officer and chief operating officer redundant

Zealand Pharma is set to make a series of restructuring changes that will shake-up a number of positions at the firm.  

The R&D arm of Zealand will be split into two parts, each with direct representation in management, while investor relations and communications will also be represented directly at management level.

As a result of the restructuring, the former positions of chief scientific officer and chief operating officer have become redundant.

Adam Steensberg, VP for development, has been promoted and appointed to the new position as senior VP for development and chief medical officer. 

The new position as senior VP for research will temporarily be filled by Keld Fosgerau, currently VP for research, while the company searches for a permanent appointment. 

Hanne Leth Hillman, VP for investor relations and corporate communications is promoted, and appointed to the new position as senior VP for investor relations and communications.

The reorganisation aims to “eliminate one management level in support of the company's strategy” and to “ensure a dynamic organisation with operational flexibility and short decision-making”.

Britt Meelby Jensen, president and CEO of Zealand, said: “I wish Adam, Keld and Hanne every success in their new roles and I look forward to working with them in their new roles.”

Article by
Ben Adams

20th March 2015

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics